Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience | BMC Cancer | Full Text

Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience | BMC Cancer | Full Text

Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience

The antibody targeting platelet-derived growth factor receptor alpha (PDGFRA), olaratumab, was approved in 2016 for metastatic soft tissue sarcoma (STS) in combination with doxorubicin based on promising resul...

Authors:Jana Käthe Striefler, Franziska Brandes, Alexander Baur, Berit Maria Pfitzner, David Kaul, Daniel Rau, Anne Dörr, Maren Schmiester, Georgios Koulaxouzidis, Lars Bullinger, Sven Märdian and Anne Flörcken

Citation:BMC Cancer 2020 20:68

Content type:Research article

Published on: 29 January 2020

• ViewFull Text
 
• ViewPDF